Skip to main content
TipRanks
Go Ultimate75% OFF

Fate Therapeutics (FATE) Stock Statistics & Valuation Metrics

1,295 Followers

Total Valuation

Fate Therapeutics has a market cap or net worth of $138.59M. The enterprise value is $228.43M.

Market Cap
$138.59M
Enterprise Value
$228.43M

Share Statistics

Fate Therapeutics has 121,568,756 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
121,568,756
Owned by Insiders
12.24%
Owned by Institutions
41.92%

Financial Efficiency

Fate Therapeutics’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -51.39%.

Return on Equity (ROE)
-0.66
Return on Assets (ROA)
-0.43
Return on Invested Capital (ROIC)
-51.39%
Return on Capital Employed (ROCE)
-0.52
Revenue Per Employee
41.28K
Profits Per Employee
-846.68K
Employee Count
161
Asset Turnover
0.02
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Fate Therapeutics is -1.09. Fate Therapeutics’s PEG ratio is -0.04.

PE Ratio
-1.09
PS Ratio
27.48
PB Ratio
1.04
Price to FCF
-1.22
Price to Operating Cash Flow
-1.31
PEG Ratio
-0.04

Income Statement

In the last 12 months, Fate Therapeutics had revenue of 6.65M and earned -136.31M in profits. Earnings per share was -1.15.

Revenue
6.65M
Gross Profit
-6.25M
Operating Income
-147.70M
Pretax Income
-136.31M
Net Income
-136.31M
EBITDA
-127.02M
Earnings Per Share (EPS)
-1.15

Cash Flow

In the last 12 months, operating cash flow was -105.46M and capital expenditures -1.51M, giving a free cash flow of -106.97M billion.

Operating Cash Flow
-105.46M
Free Cash Flow
-106.97M
Free Cash Flow per Share
-0.87

Dividends & Yields

Fate Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-80.86%
Earnings Yield
-88.66%

Stock Price Statistics

Beta
2.70
52-Week Price Change
18.26%
50-Day Moving Average
2.15
200-Day Moving Average
2.00
Relative Strength Index (RSI)
20.88
Average Volume (3m)
1.46M

Important Dates

Fate Therapeutics upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 01, 2027
Ex-Dividend Date
―

Financial Position

Fate Therapeutics as a current ratio of 5.79, with Debt / Equity ratio of 37.57%

Current Ratio
5.79
Quick Ratio
5.79
Debt to Market Cap
0.63
Net Debt to EBITDA
-0.25
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Fate Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Fate Therapeutics EV to EBITDA ratio is -1.42, with an EV/FCF ratio of -1.52.

EV to Sales
34.28
EV to EBITDA
-1.42
EV to Free Cash Flow
-1.52
EV to Operating Cash Flow
-1.54

Balance Sheet

Fate Therapeutics has $139.13M in cash and marketable securities with $74.49M in debt, giving a net cash position of $64.64M billion.

Cash & Marketable Securities
$139.13M
Total Debt
$74.49M
Net Cash
$64.64M
Net Cash Per Share
$0.53
Tangible Book Value Per Share
$1.08

Margins

Gross margin is -17.81%, with operating margin of -2760.04%, and net profit margin of -2619.64%.

Gross Margin
-17.81%
Operating Margin
-2760.04%
Pretax Margin
-2619.64%
Net Profit Margin
-2619.64%
EBITDA Margin
-2419.98%
EBIT Margin
-2657.62%

Analyst Forecast

The average price target for Fate Therapeutics is $5.13, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$5.13
Price Target Upside
349.56% Upside
Analyst Consensus
Moderate Buy
Analyst Count
6
Revenue Growth Forecast
-33.45%
EPS Growth Forecast
21.90%

Scores

Smart Score
4
AI Score
42